What is NuvoAir?
NuvoAir operates at the intersection of technology and healthcare, providing a comprehensive digital health platform designed for the proactive management of chronic conditions such as COPD, asthma, cystic fibrosis, IPF, and ALS. The NuvoAir Home platform integrates connected devices with high-touch care coordination and coaching services. This approach empowers both patients and their healthcare providers to achieve better health outcomes while simultaneously reducing healthcare costs. The company's reach extends globally, supporting thousands of patients. Furthermore, NuvoAir's decentralized clinical trial solution has been instrumental in over 30 global studies across all phases of drug development, facilitating more efficient and patient-centric research.
How much funding has NuvoAir raised?
NuvoAir has raised a total of $23M across 2 funding rounds:
Series A
$12M
Series A
$11M
Series A (2021): $12M with participation from KAYA, Albion Capital Group, Amino Collective, Spiltan, and Industrifonden
Series A (2022): $11M led by Hikma Ventures
Key Investors in NuvoAir
Hikma Ventures
Hikma Ventures is the corporate venture capital arm of Hikma Pharmaceuticals, focusing on investments in innovative healthcare technologies and companies that align with Hikma's strategic interests in pharmaceuticals and healthcare services.
Albion Capital Group
Albion Capital Group is a venture capital firm that invests in high-growth technology and healthcare companies, often focusing on businesses with strong intellectual property and scalable business models.
Industrifonden
Industrifonden is a Swedish venture capital fund that invests in unique, scalable innovations aimed at improving society through breakthrough technologies and science, with a focus on deep tech and life sciences.
What's next for NuvoAir?
With the recent influx of major strategic investment, NuvoAir is poised for accelerated growth and expansion. The company's focus on decentralized clinical trials aligns with the evolving landscape of pharmaceutical research, offering a more agile and effective model. Continued investment will likely fuel further development of its Home platform, enhancing its capabilities in chronic disease management and potentially broadening its therapeutic area support. Strategic partnerships and technological advancements are anticipated as NuvoAir solidifies its position as a leader in digital health innovation.
See full NuvoAir company page
